SANTA CLARA, Calif.--(BUSINESS WIRE)--Affymetrix, Inc. (Nasdaq:AFFX) today announced that its technology was used by the Cincinnati Children’s Hospital Medical Center to develop an innovative molecular diagnostic test designed to help diagnose the genetic defects in patients with inheritable forms of jaundice. Jaundice is the most common symptom of liver disease in young children. Cincinnati Children’s has made the CLIA- and CAP-approved laboratory developed test available to clinicians around the world.
